Search Results: Prevention, Detection & Risk + Breast Cancer (11 results)

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

• People with an inherited mutation in BRCA1, BRCA2, or PALB2 who are planning to undergo a risk-reducing mastectomy.
• For people diagnosed with stage 2 or stage 3 triple-negative breast cancer at high risk for recurrence.

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website. 

This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.

This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers. 

The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap). 

This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.

The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.